

A Rare Case Study of BRASH Syndrome

Received: 20 August 2022, **Revised:** 28 September 2022, **Accepted:** 23 October 2022

Dr Suresh Kanna S, Dr Kunduru Dinesh Reddy, Dr Kavuru Naga Siri, Dr Akhila Kosuri , Dr. Keerthana

Department of General Medicine, Sree Balaji Medical College and Hospital, Chrompet, Chennai, Tamil Nadu, India.

Corresponding Author Mail ID:

kdreddy.dmcl500@gmail.com

Keywords

Bradycardia, Renal Failure, Av Nodal Blocking Agents, Shock, Hyperkalemia

Abstract

BRASH syndrome in a combination of clinical findings resulting in patients with baseline renal failure on long term AV nodal blocking agents. Our case is a patient on long term AV nodal blocker who came with complaints of light headedness and further was diagnosed as BRASH syndrome. Initially the patient's will be started on intravenous fluids, administration of calcium gluconate, intravenous dextrose and insulin.

1. Introduction

Bradycardia [1], renal failure [3], AV nodal blockers, Shock and Hyperkalaemia [2,4,6] is a collection of findings of a synergistic cycle, often fatal, occurring in renal failure patients taking AV nodal blockers. It is often under diagnosed and not recognised, easily confusing with other etiology of the presenting clinical symptoms.

2. Case Report

A 60 years old female was brought to the ER with complaints of giddiness and light headedness for 1 day, and a near syncope episode. On the way to ER she had of heightened complaints of the same, but no history of loss of consciousness. There was no history suggestive of trauma, loss of consciousness, blacking out of vision, seizures [7]. No history of nausea, vomiting, ear pain and headache. She was a known case of Type 2 DM, Systemic hypertension, CAD and hyperlipidaemia and was on regular medications.

The patient was drowsy, oriented to time, place and person and was afebrile. She was moderately built and nourished. On monitoring the vitals, the heart rate was irregular and 39 beats per minute, Blood pressure was 90/50mmhg, reduced breath sounds on both sides and the respiratory rate was 25 per minute, spO2 was 99% at 6L of oxygen. Other systemic examinations were insignificant.

Investigations showed raised BNP values 1650pg/ml, serum creatinine was 2.3mg/dl, BUN 33mg/dl, serum potassium was 6.5mEq/l, lactate was 5.4mmol/l.

Her history revealed the long term use of T CARVEDILOL, and renal failure [3], on examination bradycardia was revealed, investigation showed Hyperkalaemia [2,4,6] leading to the primary diagnosis of BRASH syndrome.

The patient was started on IV fluid normal saline 1L bolus and Calcium gluconate. The patient improved clinically with the treatment.




Figure 1 ECG changes

3. Discussion

BRASH Syndrome is usually seen in elderly patients with cardiovascular pathology with chronic usage of chronotropic drugs or renal dysfunction with reduced reserve, triggered by hypovolemia leading to synergistic bradycardia, and Hyperkalaemia. However in the setting of this syndrome I, Hyperkalaemia is not as extreme as in other usual cases. And also this syndrome is to be kept in mind before prescribing long term AV blockers to patients with pre-existing comorbidities. Despite numerous

cases presenting with similar clinical signs and symptoms, this syndrome can be uniquely picked from the lot with careful observation and monitoring. The clinical symptoms can vary on a wide range of asymptomatic brady cardia to multiple organ failure. The basic treatment is to treat each component of the syndrome; fluid administration in case of hypovolemia [5], intracellular potassium shifting initiated with calcium gluconate for stabilization of membrane along with intravenous dextrose and insulin administration.




Figure 2: Mechanism of BRASH SYNDROME

Journal of Coastal Life Medicine

4. Conclusion

It is vividly known that BRASH syndrome in chronic chronotropic drug usage presents with bradycardia and Hyperkalaemia [6] and sometimes hypotension. After evaluation of the patient, initial treatment should be focused on fluid correction and potassium level correction. Careful prescription and follow up of patients should be ensured.

Acknowledgements

The authors are thankful to department of general medicine, Sree Balaji Medical College & hospital, Chennai, Tamil Nadu, India for the continuous support towards this research study

Ethical Consent

Patients included in the study had provided informed consent

Funding

No funding used to conduct study

Conflict of Interest

The authors declare that there was no conflict of interest

References

1. Simmons T, Blazar E: Synergistic bradycardia from beta blockers, hyperkalemia, and renal failure. *J Emerg Med*. 2019, 57:41-44. 10.1016/j.jemermed.2019.03.039
2. Arnsdorf MF, Schreiner E, Gambetta M, Friedlander I, Childers RW: Electrophysiological changes in the canine atrium and ventricle during progressive hyperkalaemia: electrocardiographical correlates and the in vivo validation of in vitro predictions. *Cardiovasc Res*. 1977, 11:409-418. 10.1093/cvr/11.5.409
3. Aziz EF, Javed F, Korniyenko A, et al.: Mild hyperkalemia and low eGFR a tedious recipe for cardiac disaster in the elderly: an unusual reversible cause of syncope and heart block. *Heart Int*. 2011, 6:12.
4. Juvet T, Gourineni VC, Ravi S, Zarich SW: Life-threatening hyperkalemia: a potentially lethal drug combination. *Conn Med*. 2013, 77:491-493
5. Argulian E: An unusual case of syncope. *Am J Med*. 2009, 122:636-638. 10.1016/j.amjmed.2009.03.017
6. PulmCrit. BRASH syndrome: bradycardia, renal failure, AV blocker, shock, hyperkalaemia. (2016). Accessed: February 15, 2020: <https://emcrit.org/pulmcrit/brash-syndromebradycardia-renal-failure-av-blocker-shock-hyperkalemia/>.
7. Jefferson AL, Poppas A, Paul RH, Cohen RA. Systemic hypoperfusion is associated with executive dysfunction in geriatric cardiac patients. *Neurobiol Aging*. 2007;28:477-83.